Skip to content
MARKETS / BALCAO / AYRWF
BALCAO · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS

Ayr Wellness Inc. AYRWF

3 fiscal years on record · USD · FY2024 reported · SEC filings only
$463.6M
▲ 0.0% YoY
$-359.3M
$-8.1M
In brief

What this company does

The Company vertically integrates cultivation, production, distribution and dispensation of cannabis brands and products. Its current portfolio of consumer-packaged goods brands includes three core brands, kynd, HAZE, and Later Days, along with an additional portfolio of legacy and local brands. As of December 31, 2024, Ayr operated 97 retail stores. As of December 31, 2024, the Company had operations in eight U.S. states and employed roughly 2,440 people. Through its subsidiaries and affiliates, the Company holds, operates and manages licenses and permits in Florida, Illinois, Massachusetts, Nevada, New Jersey, Ohio, Pennsylvania, Connecticut, New York and Virginia. The Company does not have any foreign operations outside of the United States. Ayr Wellness Inc. was founded in 2019 and has been headquartered in Miami, Florida since 2021.

Written from the business description in Ayr Wellness Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 24 March 2025. Every sentence was checked against that document before publication.

Growth
USD 463.6M
Revenue, FY2024 · full 3-year series below
Revenue $M Net income $M
FY2024 · Revenue 463.6 · Net income -359.3
200M400M-200M202220232024
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−78 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -34.7% · Net -78.2%
-20%-40%-60%202220232024
ROE
FY2024 · ROE -74.8%
-20%-40%-60%202220232024

Each USD of equity lost 75 cents this year.

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -8.1
-40M-80M202220232024

Total assetsUSD 1.3B
EquityUSD 379.5M
CashUSD 35.5M
Gross debtUSD 410.5M
Net debtUSD 375.0M
Current ratio1.60×

Net debt stands at 99% of equity.

The 3-year record
3 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202420232022
Revenue $B0.50.50.4
Operating income $B−0.2−0.0−0.2
EBITDA $B−0.1−0.0−0.2
Income tax $B0.00.00.0
Net income $B−0.4−0.3−0.2
Free cash flow $B−0.0−0.0−0.1
EPS, diluted $−3.24−3.68−3.58
Dividend / sh $···
Payout %···
ROE %−74.8−38.5−29.5

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 15 reconciliationsAUDITED

Reconciled in 3 of 19 fiscal years. 80 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityMedicinal Chemicals & Botanical Products
Listed onOTC market
Incorporated inoutside the United States — SEC code A1
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2022

Share this section

Download image